BIT Capital GmbH Has $964,000 Stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Key Points

• BIT Capital GmbH reduced its stake in BioNTech SE by 45.7%, selling 8,894 shares and bringing its total holdings down to 10,586 shares worth approximately $964,000.
• Several institutional investors have altered their positions in BioNTech, with notable increases from Whittier Trust Co. and Tower Research Capital LLC, highlighting a shift in investor interest.
• Currently, BioNTech has a consensus rating of "Moderate Buy" with a price target of $136.58, according to a variety of analysts including Truist Financial and Morgan Stanley.

BIT Capital GmbH lowered its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 45.7% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,586 shares of the company's stock after selling 8,894 shares during the quarter. BIT Capital GmbH's holdings in BioNTech were worth $964,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of BNTX. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech during the first quarter valued at approximately $36,000. Goodman Advisory Group LLC purchased a new stake in BioNTech during the first quarter valued at approximately $105,000. Whittier Trust Co. raised its holdings in shares of BioNTech by 3,846.2% in the first quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after buying an additional 2,000 shares during the period. Tower Research Capital LLC TRC boosted its position in BioNTech by 61.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after acquiring an additional 713 shares in the last quarter. Finally, Probity Advisors Inc. boosted its position in shares of BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 0.9%

BNTX traded down $0.95 during trading on Wednesday, reaching $110.12. The stock had a trading volume of 350,082 shares, compared to its average volume of 947,820. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a one year low of $78.39 and a one year high of $131.49. The company has a market capitalization of $26.47 billion, a price-to-earnings ratio of -69.00 and a beta of 1.23. The stock's 50 day moving average is $108.59 and its two-hundred day moving average is $106.20.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.85%. The firm had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same period last year, the firm earned ($3.36) earnings per share. The company's revenue for the quarter was up 102.6% on a year-over-year basis. As a group, analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

BNTX has been the subject of several research reports. Bank of America boosted their price objective on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research note on Tuesday. Leerink Partners set a $112.00 target price on shares of BioNTech in a research note on Monday, June 2nd. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Truist Financial reaffirmed a "buy" rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Finally, HC Wainwright restated a "buy" rating and set a $138.00 target price on shares of BioNTech in a report on Wednesday, June 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $135.91.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.